Extracorporeal Photopheresis for the Inpatient Dermatologist

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Current Dermatology Reports

• Publication date

  2025-11-19

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/s13671-025-00486-8
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Extracorporeal photopheresis induces the release of anti-inflammatory fatty acids and oxylipins and suppresses pro-inflammatory sphingosine-1-phosphate

  2025cited by this paper
• Outcomes of extracorporeal photopheresis in a diverse cohort of patients with cutaneous T-cell lymphoma: a retrospective study at a tertiary care hospital

  2024cited by this paper
• Improving disease‐specific survival for patients with Sezary syndrome in the modern era of systemic therapies

  2024cited by this paper
• Complete Remission of Tumour-Stage Mycosis Fungoides with Combined Chlormethine Gel and Local Low-Dose Radiotherapy in a Patient Under Extracorporeal Photopheresis

  2024cited by this paper
• Dimethyl fumarate and extracorporeal photopheresis combination-therapy synergize in inducing specific cell death and long-term remission in cutaneous T cell lymphoma

  2024cited by this paper
• On the Way to Curing Advanced-Stage Mycosis Fungoides/Sézary Syndrome.

  2024cited by this paper
• Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019

  2024cited by this paper
• Sézary Syndrome in West Sweden: Exploring Epidemiology, Clinical Features, and Treatment Patterns in a Registry-Based Retrospective Analysis

  2024cited by this paper
• Sustained Complete Remission in Sézary Syndrome using Extracorporeal Photopheresis: A Multicentric Case Series

  2024cited by this paper
• International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies

  2023influential reference
• The potential association between extracorporeal photopheresis and thrombosis

  2023cited by this paper
• Boost of innate immunity cytokines as biomarkers of response to extracorporeal photopheresis in leukaemic cutaneous T-cell lymphoma patients.

  2023influential reference
• EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2023.

  2023cited by this paper
• Sustained complete remission in Sézary syndrome using extracorporeal photopheresis: a multicentric case series

  2023cited by this paper
• Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers

  2023cited by this paper
• Effects of Extracorporeal Photopheresis on Quality of Life and the Course of Diseases in Patients With Mycosis Fungoides and Graft-Versus-Host Disease: A Single-Center Analysis

  2023cited by this paper
• Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study

  2023cited by this paper
• EXTRACORPOREAL PHOTOPHERESIS IN GRAFT-VERSUS-HOST DISEASE.

  2023cited by this paper
• Efficacy and safety of offline extracorporeal photopheresis in cutaneous T‐cell lymphomas: A retrospective study

  2023cited by this paper
• Mogamulizumab Combined with Extracorporeal Photopheresis as a Novel Therapy in Erythrodermic Cutaneous T-cell Lymphoma

  2023cited by this paper
• Mogamulizumab combined with extracorporeal photopheresis for the treatment of refractory mycosis fungoides and Sézary syndrome. Report of seven cases

  2023cited by this paper
• Extracorporeal photopheresis as a treatment for patients with cutaneous T‐cell lymphoma: real‐world data at a reference cancer centre in Colombia

  2022cited by this paper
• Cost-Effectiveness of Extracorporeal Photopheresis for the Treatment of Patients With Erythrodermic (Stage T4, M0) Cutaneous T-Cell Lymphoma in the Australian Setting.

  2022cited by this paper
• Pre-transplant infusion of donor leukocytes treated with extracorporeal photochemotherapy induces immune hypo-responsiveness and long-term allograft survival in murine models

  2022cited by this paper
• Outcome of extracorporeal photopheresis in mycosis fungoides patients is not predicted by quotients of systemic immune‐inflammatory biomarkers

  2022cited by this paper
• Impact of extracorporeal photopheresis on blood and coagulation parameters

  2022cited by this paper
• Analysis of clinical and serologic predictors of response to extracorporeal photopheresis therapy in cutaneous T‐cell lymphoma patients

  2022cited by this paper
• Cost-Effectiveness of Extracorporeal Photopheresis for the Treatment of Patients With Erythrodermic Stage T4, M0) Cutaneous T-Cell Lymphoma in the Australian Setting.

  2022cited by this paper
• Monitoring malignant T‐cell clones by direct TCR expression assay in patients with leukemic cutaneous T‐cell lymphoma during extracorporeal photopheresis

  2021cited by this paper
• Extracorporeal photopheresis and multimodality therapy in patients with T‐cell cutaneous lymphomas: Real‐life experience in Argentina

  2021cited by this paper
• Real-world use of extracorporeal photopheresis for patients with cutaneous T-cell lymphoma in the United States: 2010–2015

  2020cited by this paper
• European dermatology forum – updated guidelines on the use of extracorporeal photopheresis 2020 – part 1

  2020influential reference
• NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020.

  2020cited by this paper
• Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue

  2019cited by this paper
• Extracorporeal photochemotherapy induces bona fide immunogenic cell death

  2019cited by this paper
• Extracorporeal Photopheresis—An Overview

  2018cited by this paper
• An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma

  2018cited by this paper
• The role of extracorporeal photopheresis in the management of cutaneous T‐cell lymphoma, graft‐versus‐host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society

  2017influential reference
• Extracorporeal photopheresis practice patterns: An international survey by the ASFA ECP subcommittee

  2017cited by this paper
• Photopheresis: Advances and Use in Systemic Sclerosis

  2017cited by this paper
• 75% Complete Response and 15% Partial Response to Extracorporeal Photopheresis Combined With Other Therapies in Resistant Early Stage Cutaneous T-Cell Lymphoma.

  2016cited by this paper
• The Successful Use of Extracorporeal Photopheresis in a 12‐Year‐Old Patient with Refractory Epidermolysis Bullosa Acquisita

  2015cited by this paper
• Early changes in miRNA expression are predictive of response to extracorporeal photopheresis in cutaneous T‐cell lymphoma

  2015cited by this paper
• Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy.

  2015influential reference
• Integrin‐driven monocyte to dendritic cell conversion in modified extracorporeal photochemotherapy

  2014cited by this paper
• Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T‐cell lymphoma: a single center clinical experience with long‐term follow‐up data and a brief overview of the literature

  2013cited by this paper
• Guidelines on the use of extracorporeal photopheresis

  2013influential reference
• Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue

  2013cited by this paper
• Long‐term follow‐up and survival of cutaneous T‐cell lymphoma patients treated with extracorporeal photopheresis

  2012cited by this paper
• Diagnosis and management of chronic graft‐versus‐host disease

  2012cited by this paper
• The role of extracorporeal photopheresis in the treatment of cutaneous T-cell lymphomas.

  2012cited by this paper
• Photopheresis in the treatment of cutaneous T-cell lymphoma: current status

  2012cited by this paper
• Diagnosis and management of acute graft‐versus‐host disease

  2012cited by this paper
• Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC).

  2011cited by this paper
• High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of response.

  2011cited by this paper
• Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease.

  2011cited by this paper
• Circulating B-cell activating factor level predicts clinical response of chronic graft-versus-host disease to extracorporeal photopheresis.

  2011cited by this paper
• The role of photopheresis in the treatment of graft-versus-host disease.

  2010cited by this paper
• Predictors of response to extracorporeal photopheresis in advanced mycosis fungoides and Sézary syndrome

  2010cited by this paper
• Effect of UVA and 8-methoxypsoralen, 4, 6, 4'-trimethylangelicin or chlorpromazine on apoptosis of lymphocytes and their recognition by monocytes.

  2010cited by this paper
• Extracorporeal photopheresis: what is it and when should it be used?

  2009cited by this paper
• Extracorporeal photopheresis in graft‐versus‐host disease

  2008cited by this paper
• Experimental Extracorporeal Photopheresis Inhibits the Sensitization and Effector Phases of Contact Hypersensitivity via Two Mechanisms: Generation of IL-10 and Induction of Regulatory T Cells1

  2008influential reference
• Extracorporeal Photochemotherapy Is Accompanied by Increasing Levels of Circulating CD4+CD25+GITR+Foxp3+CD62L+ Functional Regulatory T-Cells in Patients With Graft-Versus-Host Disease

  2007cited by this paper
• Extracorporeal photochemotherapy in patients with cutaneous T‐cell lymphoma: is clinical response predictable?

  2006cited by this paper
• Extracorporeal Photopheresis for the Treatment of Cutaneous T-Cell Lymphoma

  2003cited by this paper
• Short-term and long-term cellular and molecular events following UV irradiation of skin: implications for molecular medicine

  2002cited by this paper
• Treatment of Cutaneous T Cell Lymphoma

  2002cited by this paper
• Extracorporeal photochemotherapy: a case report and update.

  2002cited by this paper
• Circulating CD4+CD7- lymphocyte burden and rapidity of response: predictors of outcome in the treatment of Sézary syndrome and erythrodermic mycosis fungoides with extracorporeal photopheresis.

  2002cited by this paper
• Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution.

  2002cited by this paper
• Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.

  2001cited by this paper
• Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides.

  2000cited by this paper
• The National Comprehensive Cancer Network

  1998cited by this paper
• Extracorporeal photochemotherapy restores Th1/Th2 imbalance in patients with early stage cutaneous T‐cell lymphoma

  1997cited by this paper
• Treatment of cutaneous T‐cell lymphoma with extracorporeal photochemotherapy

  1996cited by this paper
• Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma — the Düsseldorf and Munich experience

  1995cited by this paper
• EXTRACORPOREAL PHOTOPHERESIS

  1994cited by this paper
• Parenteral administration of 8-methoxypsoralen in photopheresis.

  1993cited by this paper
• Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy.

  1992cited by this paper
• Extracorporeal Photochemotherapy Induces the Production of Tumor Necrosis Factor-α by Monocytes: Implications for the Treatment of Cutaneous T-Cell Lymphoma and Systemic Sclerosis

  1992cited by this paper
• Treatment of rheumatoid arthritis by extracorporeal photochemotherapy. A pilot study.

  1991cited by this paper
• Extracorporeal photopheresis in psoriasis vulgaris: clinical and immunologic observations.

  1990cited by this paper

• No citing papers are available for this paper.